Results 1 to 10 of about 104,712 (155)

CldU sensitizes <i>BRCA2</i> reverse-mutated cells to PARP inhibitors. [PDF]

Front Oncol
PARP inhibitors are widely used class of drugs for the treatment of homologous recombination deficient cancers, including BRCA mutated ones. These drugs led to substantial improvement in survival, particularly for patients with BRCA mutated tumors ...
Zouggari N, Trugenberger C, Du Bois V, Wang W, Rossetti GG, Halazonetis TD, Labidi-Galy I.   +6 more
europepmc   +2 more sources

PARP inhibitors combined with radiotherapy: are we ready?

Frontiers in Pharmacology, 2023
PARP was an enzyme found in the nucleus of eukaryotic cells that played a crucial role in repairing damaged DNA. Recently, PARP inhibitors have demonstrated great potential in cancer treatment.
Alan Chu, Rui Song
exaly   +3 more sources

PARP inhibitors in melanoma treatment: potential, challenges, and future directions. [PDF]

Front Oncol
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression.
Anaeme A, Moussa K, Mansour AN, Nassief G, Ansstas G.   +4 more
europepmc   +2 more sources

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

Therapeutic Advances in Medical Oncology, 2017
Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer.
Ursula A Matulonis
exaly   +2 more sources

Structural Implications for Selective Targeting of PARPs. [PDF]

Frontiers in Oncology, 2013
Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that use NAD(+) as a substrate to synthesize polymers of ADP-ribose (PAR) as post-translational modifications of proteins.
Armen, MD, Roger S, Brody, MD, Jonathan, Pascal, MD, John M, Steffen, MD, Jamin D   +3 more
core   +5 more sources

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

Frontiers in Pharmacology, 2022
Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical ...
Xi Zhang, Xiao Huo, Xiao Huo, Hongyan Guo, Lixiang Xue, Lixiang Xue   +5 more
doaj   +1 more source

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells [PDF]

, 2012
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner.
Barna, Gabor, Bauer, Pal I., Dunai, Zsuzsanna A., Imre, Gergely, Korcsmaros, Tamas, Mihalik, Rudolf, Petak, Istvan   +6 more
core   +13 more sources

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

Frontiers in Oncology, 2023
Polyadenosine diphosphate-ribose polymerase (PARP) is a key modifying enzyme in cells, which participates in single-strand break repair and indirectly affects double-strand break repair.
Yi Zhang, Lijie Liang, Zheng Li, Ying Huang, Ming Jiang, Bingwen Zou, Yong Xu   +6 more
doaj   +1 more source

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression [PDF]

, 2015
To overcome cancer cells resistance to pharmacological therapy, the development of new therapeutic approaches becomes urgent. For this purpose, the use of poly(ADP-ribose) polymerase (PARP) inhibitors in combination with other cytotoxic agents could ...
CAIAFA, Paola, CALABRESE, ROBERTA, CICCARONE, FABIO, Daniela Trisciuoglio, Donatella Del Bufalo, GUASTAFIERRO, Tiziana, MARIANO, GERMANO, REALE, Anna, RICCIARDI, Maria Rosaria, TAFURI, Agostino, VALENTINI, ELISABETTA, ZAMPIERI, Michele   +11 more
core   +8 more sources

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
The poly (ADP-ribose) polymerase (PARP) inhibitors play a crucial role in cancer therapy. However, most approved PARP inhibitors cannot cross the blood-brain barrier, thus limiting their application in the central nervous system. Here, 55 benzodiazepines
Jiang Yu, Wenfeng Gou, Haihua Shang, Yating Cui, Xiao Sun, Lingling Luo, Wenbin Hou, Tiemin Sun, Yiliang Li   +8 more
doaj   +1 more source